Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.

Cihlar T, He GX, Liu X, Chen JM, Hatada M, Swaminathan S, McDermott MJ, Yang ZY, Mulato AS, Chen X, Leavitt SA, Stray KM, Lee WA.

J Mol Biol. 2006 Oct 27;363(3):635-47. Epub 2006 Aug 2.

PMID:
16979654
2.

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs.

Cihlar T, Ho ES, Lin DC, Mulato AS.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8.

PMID:
11563082
3.

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):450-8.

PMID:
11511821
5.

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM.

Antivir Ther. 1999;4(2):87-94.

PMID:
10682153
8.

Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

Miller MD, Lamy PD, Fuller MD, Mulato AS, Margot NA, Cihlar T, Cherrington JM.

Mol Pharmacol. 1998 Aug;54(2):291-7.

PMID:
9687570
9.

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.

Mulato AS, Lamy PD, Miller MD, Li WX, Anton KE, Hellmann NS, Cherrington JM.

Antimicrob Agents Chemother. 1998 Jul;42(7):1620-8.

10.

In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).

Xiong X, Flores C, Fuller MD, Mendel DB, Mulato AS, Moon K, Chen MS, Cherrington JM.

Antiviral Res. 1997 Nov;36(2):131-7.

PMID:
9443670
11.
12.

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.

Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J.

J Infect Dis. 1997 Dec;176(6):1517-23.

PMID:
9395363
13.

9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.

Van Rompay KK, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, Tarara RP, Canfield DR, Telm S, Bischofberger N, Pedersen NC.

Antimicrob Agents Chemother. 1996 Nov;40(11):2586-91.

14.
15.

Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.

Cherrington JM, Fuller MD, Mulato AS, Allen SJ, Kunder SC, Ussery MA, Lesnikowski Z, Schinazi RF, Sommadossi JP, Chen MS.

Antimicrob Agents Chemother. 1996 May;40(5):1270-3.

16.

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.

Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM, Wainberg MA.

Antimicrob Agents Chemother. 1995 Aug;39(8):1888-91.

Supplemental Content

Loading ...
Support Center